Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Maspin marker may predict breast cancer relapse:

This article was originally published in Clinica

Executive Summary

Measuring levels of a protein called maspin in certain breast cancer patients could help doctors identify those more likely to suffer a relapse following therapy, according to preliminary results from an Italian study. In an assessment of 48 high-risk breast cancer patients with a micrometastatic disease, those with higher levels of the protein were less likely to relapse, reported researchers from the European Institute of Oncology in Milan. Of 10 women with 20 or more lymph nodes affected by the disease, eight who had high levels of maspin did not relapse at a 15 month-follow-up, while the remaining two with low levels of the protein developed secondary cancers.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT074961

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel